查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990330

固態器官移植排斥反應市場：依排斥反應類型、移植方式、器官類型及最終用戶分類－2026-2032年全球市場預測

Solid Organ Transplantation Rejection Market by Rejection Type, Offering, Organ Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，固態器官移植排斥反應市場價值將達到 91.9 億美元，到 2026 年將成長至 96.7 億美元，到 2032 年將達到 134.1 億美元，複合年成長率為 5.54%。

主要市場統計數據
基準年 2025 91.9億美元
預計年份：2026年 96.7億美元
預測年份 2032 134.1億美元
複合年成長率 (%) 5.54%

固態器官移植排斥反應的臨床、診斷和治療環境不斷變化，以及綜合護理路徑和創新面臨的策略挑戰。

固態器官移植仍然是現代醫學中最具突破性的治療方法之一，但排斥反應仍然是臨床和運作中面臨的核心挑戰。隨著手術效果的改善，人們的關注點正轉向導致急性、慢性及超急性排斥反應的各種免疫反應，每種反應都需要獨特的診斷、監測和治療方法。隨著免疫學、診斷學和治療學之間相互作用的不斷發展，臨床醫生、醫院系統、製造商和保險公司需要重新評估治療路徑及其相關基礎設施。

診斷、治療、數位整合、監管重點和跨部門合作方面的變革性轉變正在重塑移植排斥反應的檢測和管理方式。

目前，移植排斥反應的管理正經歷多項平行變革，這些變革共同重塑治療標準。其中一項關鍵變革是精準診斷技術的成熟。血液檢測、先進影像技術和精密組織切片檢查技術的融合，使得免疫介導性疾病的早期和特異性檢測成為可能。診斷技術的進步與免疫調節藥物的改進相輔相成，包括先進的抗體療法、標靶抗代謝藥物、最佳化的Calcineurin酶抑制劑方案以及類固醇減量策略，這些都為更個人化的免疫抑制療法創造了可能，從而降低排斥反應和長期毒性。

本研究評估了 2025 年起生效的美國關稅變化將如何影響移植醫學的器官來源、製造地、國際合作和供應鏈韌性。

自2025年起，美國將實施關稅，這將進一步加劇現有供應鏈的壓力，促使移植醫學領域的眾多相關人員重新評估籌資策略。血液檢測、影像平台和組織切片檢查處理中使用的設備和試劑通常依賴跨國供應鏈。因此，不斷上漲的進口成本和日益複雜的海關程序正在影響採購決策、庫存管理和供應商多元化。為此，一些移植中心和專科診所正在加快關鍵庫存在地採購的步伐，協商簽訂多年期供應商契約，或採用使用更多國內可得組件的替代技術。

針對特定細分市場的洞察，整合了排斥表現型、診斷方法、治療藥物分類、器官特異性考慮因素以及醫療保健環境的影響，從而指導策略優先排序。

透過檢驗構成移植排斥反應管理的關鍵環節，可以更深入了解市場動態。從排斥反應類型來看，急性排斥反應需要快速診斷和立即進行免疫抑制；慢性排斥反應需要長期監測和採取措施來減輕移植器官的進行性劣化；而超急性排斥反應則需要在術前和術後即時進行識別和干涉。因此，每種排斥反應表現型都有其獨特的臨床重點和技術要求。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和採用模式決定了研究重點、臨床整合以及移植創新成果的取得途徑。

區域差異顯著影響著預防和管理移植排斥反應的創新技術如何引入並融入醫療保健系統。在美洲，高移植中心和完善的報銷機制通常有利於先進診斷技術和新型治療方法的快速應用，而區域間醫療資源取得的差異則需要採取針對性措施來擴大醫療能力並確保醫療服務的公平性。在歐洲、中東和非洲，法律規範和醫療體系模式各不相同。因此，技術的實施往往不均衡，學術機構和國家級醫院主導臨床研究和最佳實踐的推廣，而其他地區則專注於實用且資源高效的方案。

這種競爭與合作的企業洞察揭示了診斷技術創新者、治療方法開發商和供應鏈策略家為獲得臨床和營運領導地位而採取的策略。

移植排斥反應管理領域的競爭格局呈現出成熟醫療公司與專業創新企業並存的局面，雙方攜手合作，共同推動技術進步與臨床應用。診斷公司正投資開發可擴展的高靈敏度血液檢測和組織分析平台，而影像供應商則專注於增強移植監測和功能評估的影像方式。製藥和生物技術公司持續最佳化免疫抑制療法，並推進針對特定免疫路徑的抗體和小分子藥物的研發，他們通常與學術機構合作，以檢驗臨床終點和安全性。

為高階主管和臨床領導者提供實用建議，以加快診斷技術的採用，加強供應鏈，協調夥伴關係關係，並在所有醫療保健機構中擴大公平獲取途徑。

產業領導者應推動一系列合作舉措，將科學進步轉化為移植存活率和患者預後的可衡量改善。首先，優先投資於能夠實現早期、非侵入性檢測的診斷技術，將提高臨床應對力，並減少對侵入性手術的依賴。其次，將由可互通的醫療資訊科技、決策支援和臨床醫生培訓支援的「診斷到治療演算法」整合到臨床工作流程中，將加速其應用，並提高各醫院、移植中心和專科診所之間護理的一致性。此外，各機構應建立策略夥伴關係，將診斷設備製造商、藥物開發商和研究機構聯合起來，共同設計檢驗研究和真實世界數據（REW）項目，以證明其在心臟、腎臟、肝臟、肺臟和胰臟移植領域的臨床效用。

我們研究途徑透明的混合方法，結契約儕審查的證據、主要專家訪談和操作檢驗，得出可靠且可操作的結論。

本報告的分析採用了一種嚴謹的混合方法研究途徑，旨在確保其可靠性、相關性和實用性。二級研究包括對同行評審的臨床文獻、監管申報文件和公開技術文件進行系統性回顧，以描述各種排斥表現型的診斷技術、治療機制和臨床管理策略。此外，還開展了一級研究，包括對移植臨床醫生、實驗室管理人員、器官捐贈者和行業高管進行結構化訪談，以了解他們對未滿足需求、推廣障礙和實際應用促進因素的觀點。

結論整合了臨床和策略需求，透過診斷、治療、協調和穩健的安置策略來提高移植存活率。

固態器官移植正處於科學創新、臨床實務和系統性考量交會的十字路口，這些因素共同影響著病患的預後。診斷和治療方法的進步具有降低急性、慢性及超急性排斥反應發生率和影響的真正潛力，但要實現這一潛力，需要製造商、臨床醫生、醫療系統和政策制定者之間的通力合作。對非侵入性監測、實證醫學、可互通的工作流程和穩健的供應鏈進行策略性投資，對於將科學進步轉化為日常臨床效益至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：固態器官移植的市場排斥－排斥的類型

  • 急性排斥反應
  • 慢性排斥
  • 超急性排斥

第9章：固態器官移植排斥反應市場：依產品供應情況分類

  • 診斷和測試解決方案
    • 驗血
    • 影像檢查
    • 組織切片檢查
  • 製藥
    • 抗體
    • 抗代謝物
    • Calcineurin抑制劑
    • 類固醇

第10章：固態器官移植排斥反應－按器官類型分類的市場

  • 心
  • 腎
  • 肝
  • 肺
  • 胰臟

第11章：固態器官移植排斥市場：依最終使用者分類

  • 醫院及移植中心
  • 研究機構
  • 專科診所

第12章：固態器官移植排斥反應市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：固態器官移植排斥反應市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：固態器官移植排斥反應市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國固態器官移植排斥市場

第16章：中國固態器官移植排斥反應市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Accord Healthcare Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Biocon
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eurofins Transplant Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Globela Pharma
  • Lupin Limited
  • Manus Aktteva Biopharma LLP
  • Natco Pharma Ltd.
  • Novartis AG
  • Panacea Biotec Pharma Ltd.
  • Pfizer Inc.
  • Plexision
  • Sanofi SA
  • Strides Pharma Global Pte Ltd.
  • Thermo Fisher Scientific Inc.
  • Veloxis Pharmaceuticals A/S
  • Zydus Lifesciences Limited
Product Code: MRR-CB04E05661AD

The Solid Organ Transplantation Rejection Market was valued at USD 9.19 billion in 2025 and is projected to grow to USD 9.67 billion in 2026, with a CAGR of 5.54%, reaching USD 13.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.19 billion
Estimated Year [2026] USD 9.67 billion
Forecast Year [2032] USD 13.41 billion
CAGR (%) 5.54%

Introducing the evolving clinical, diagnostic, and therapeutic environment of solid organ transplant rejection and the strategic imperatives for integrated care pathways and innovation

Solid organ transplantation remains one of the most transformative interventions in modern medicine, yet rejection continues to be a central clinical and operational challenge. As surgical outcomes have improved, attention has shifted to the heterogenous immune responses that lead to acute, chronic, and hyperacute rejection, each of which demands distinct diagnostic, monitoring, and therapeutic approaches. The evolving interplay between immunology, diagnostics, and therapeutics requires clinicians, hospital systems, manufacturers, and payers to re-evaluate care pathways and the supporting infrastructure.

In recent years, advances in molecular diagnostics and noninvasive monitoring have opened new possibilities for earlier detection and individualized immunosuppression, while therapeutic innovations seek to balance efficacy with long-term safety. At the same time, differences in transplanted organs-such as the physiologic and immunologic nuances of heart, kidney, liver, lung, and pancreas transplantation-shape both clinical practice and product development. Consequently, stakeholders must synthesize evidence across rejection type, diagnostic and medication offerings, organ-specific considerations, and the diverse environments in which transplant care is delivered. This introduction sets the context for a focused examination of those elements and frames the priorities that will guide clinical effectiveness, patient outcomes, and system-level value creation.

Transformative shifts in diagnostics, therapeutics, digital integration, regulatory focus, and cross-sector collaboration that are reframing how transplant rejection is detected and managed

The landscape of transplant rejection management is undergoing several parallel transformations that together are redefining standards of care. One primary shift is the maturation of precision diagnostics: blood-based assays, advanced imaging modalities, and refined tissue biopsy techniques are converging to enable earlier and more specific detection of immune-mediated injury. These diagnostic advances are complemented by improvements in immunomodulatory medications, including refined antibody therapies, targeted antimetabolites, optimized calcineurin inhibitor regimens, and steroid minimization strategies, creating opportunities for more individualized immunosuppression that reduces both rejection and long-term toxicity.

Alongside clinical innovations, digital health and data integration are changing how monitoring and decision-making occur. Remote patient monitoring, algorithmic risk stratification, and interoperable electronic health records are facilitating more proactive care and tighter coordination among transplant centers, specialty clinics, and research institutes. Regulatory and reimbursement environments are also shifting their focus toward evidence of clinical utility and cost-effectiveness, which incentivizes the development of diagnostics and therapeutics that demonstrate clear impact on outcomes. Finally, partnerships across industry, academic centers, and clinical networks are accelerating translational research and multicenter validation of novel tools. Taken together, these transformative shifts are producing a more responsive, evidence-driven approach to preventing and managing acute, chronic, and hyperacute rejection across organ types.

Assessing how United States tariff changes beginning in 2025 are reshaping procurement, manufacturing footprints, international collaborations, and supply chain resilience for transplant care

The introduction of tariffs in the United States beginning in 2025 has compounded preexisting supply chain pressures and prompted a reevaluation of procurement strategies for many stakeholders involved in transplantation care. Devices and reagents used in blood tests, imaging platforms, and tissue biopsy processing often rely on multinational supply chains; increased import costs and customs complexity have therefore influenced sourcing decisions, inventory practices, and supplier diversification. As a result, some transplant centers and specialty clinics have accelerated efforts to localize critical inventories, negotiate multi-year supplier agreements, or adopt alternative technologies with more domestically available components.

In addition to procurement adaptations, tariffs have affected collaborative dynamics with international research partners and manufacturers. Cross-border clinical trials and technology transfer arrangements have required greater attention to total landed cost, regulatory alignment, and contingency planning. Manufacturers and distributors have responded by reassessing manufacturing footprints, increasing redundancy in critical nodes of the supply chain, and prioritizing transparency in lead times and component provenance. While these adjustments have the potential to increase resilience, they also introduce transitional operational costs and require closer coordination between hospitals, transplant centers, and research institutes to maintain uninterrupted access to diagnostics and therapies. Ultimately, the cumulative impact of tariffs has underscored the need for strategic procurement, robust supplier relationships, and operational flexibility across the transplantation ecosystem.

Segment-driven insights synthesizing rejection phenotypes, diagnostic modalities, therapeutic classes, organ-specific considerations, and care setting influences to guide strategic prioritization

A nuanced understanding of market dynamics emerges by examining the key segments that define transplant rejection management. When viewing the field through the lens of rejection type, acute rejection demands rapid diagnostic clarity and responsive immunosuppression, chronic rejection requires long-term monitoring and strategies to mitigate progressive graft deterioration, and hyperacute rejection necessitates immediate perioperative recognition and intervention. Each rejection phenotype thus imposes distinct clinical priorities and technology requirements.

From the perspective of offerings, diagnostics and testing solutions encompass blood tests that permit noninvasive surveillance, imaging tests that characterize structural and perfusion changes, and tissue biopsy procedures that provide histopathologic confirmation; medications include antibody agents that modulate humoral responses, antimetabolites that interfere with lymphocyte proliferation, calcineurin inhibitors that suppress T-cell activity, and steroids used for both induction and rescue therapy. These categories interact differently across organ types: heart, kidney, liver, lung, and pancreas transplantation each present unique immunologic profiles and clinical surveillance needs that influence the choice and sequencing of diagnostics and therapeutics. Finally, end-user settings such as hospitals and transplant centers deliver comprehensive perioperative and long-term care, research institutes drive translational innovation and validation studies, and specialty clinics often support outpatient monitoring and medication optimization. An integrated view of these segmentations clarifies where clinical unmet needs intersect with technological capabilities and operational realities, enabling stakeholders to prioritize investment, development, and implementation strategies that align with organ-specific and care-setting requirements.

Regional patterns and adoption dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine research focus, clinical integration, and access to transplant innovations

Regional variation profoundly affects how innovations in transplant rejection prevention and management are adopted and integrated into care. In the Americas, high-volume transplant centers and established reimbursement pathways often support rapid uptake of advanced diagnostics and novel therapeutics, while regional disparities in access require targeted initiatives to expand capacity and equitable care. Europe, Middle East & Africa exhibit heterogeneous regulatory frameworks and health system models; as a result, adoption tends to be uneven, with academic centers and national reference hospitals leading in clinical research and the diffusion of best practices, while other areas focus on pragmatic, resource-efficient approaches.

Across Asia-Pacific, rising transplant volumes and substantial investments in biotechnology and diagnostics have spurred local innovation and manufacturing, contributing to an expanding pipeline of regionally developed tools. However, differences in population demographics, disease etiologies, and care infrastructure mean that clinical pathways and monitoring strategies are often adapted to local contexts. These geographic distinctions also influence collaborative research priorities, the design of multicenter studies, and the scalability of solutions, underscoring the importance of tailoring implementation plans and commercialization strategies to regional strengths, regulatory expectations, and health system realities.

Competitive and collaborative company insights revealing how diagnostics innovators, therapeutic developers, and supply chain strategists are positioning to capture clinical and operational leadership

The competitive landscape in transplant rejection management is characterized by a mix of established healthcare companies and specialized innovators that together drive technological progress and clinical adoption. Diagnostic firms are investing in high-sensitivity blood-based assays and scalable platforms for tissue analysis, while imaging vendors focus on modalities that enhance graft surveillance and functional assessment. Pharmaceutical and biotech companies continue to refine immunosuppressive regimens and advance antibody and small-molecule programs that target specific immune pathways, often collaborating with academic centers to validate clinical endpoints and safety profiles.

Strategic partnerships, co-development agreements, and licensing arrangements are common as organizations seek to combine diagnostic precision with therapeutic innovation. In addition, manufacturers are responding to supply chain pressures by diversifying supplier networks and exploring near-shore manufacturing to reduce vulnerability to international disruptions. Overall, the market exhibits a pragmatic balance between competition and collaboration: firms that demonstrate interoperability with clinical workflows, robust evidence of clinical utility, and reliable supply chains are best positioned to form durable relationships with hospitals, transplant centers, and research institutes.

Actionable recommendations for senior executives and clinical leaders to accelerate diagnostic adoption, strengthen supply chains, align partnerships, and expand equitable access across care settings

Industry leaders should pursue a set of coordinated actions to translate scientific advances into measurable improvements in graft longevity and patient outcomes. First, prioritizing investments in diagnostics that enable earlier, noninvasive detection will improve clinical responsiveness and reduce reliance on more invasive procedures. Secondly, embedding diagnostic-to-therapy algorithms into clinical workflows-supported by interoperable health IT, decision support, and clinician training-will accelerate adoption and improve consistency of care across hospitals, transplant centers, and specialty clinics. Moreover, organizations should pursue strategic partnerships that unite diagnostic makers, pharmaceutical developers, and research institutes to co-design validation studies and real-world evidence programs that demonstrate clinical utility across heart, kidney, liver, lung, and pancreas transplantation.

From an operational perspective, supply chain diversification and transparent supplier relationships are essential to mitigate the downstream effects of trade policies and component shortages. Leaders must also focus on equitable access strategies that address geographic disparities and support capacity building where adoption lags. Finally, corporate and clinical stakeholders should invest in post-market surveillance and longitudinal registries to better understand patterns of acute, chronic, and hyperacute rejection and to refine therapeutic strategies over time. Taken together, these actions will help organizations reduce clinical variability, optimize resource utilization, and expand patient access to state-of-the-art monitoring and treatment.

Transparent mixed-methods research approach integrating peer-reviewed evidence, primary expert interviews, and operational validation to ensure robust and actionable conclusions

The analysis underpinning this report combines a rigorous, mixed-methods research approach designed to ensure credibility, relevance, and practical utility. Secondary research included a systematic review of peer-reviewed clinical literature, regulatory filings, and publicly available technical documentation to characterize diagnostic technologies, therapeutic mechanisms, and clinical management strategies for different rejection phenotypes. This evidence base was supplemented by primary research consisting of structured interviews with transplant clinicians, laboratory directors, procurement officers, and industry executives to capture frontline perspectives on unmet needs, implementation barriers, and practical adoption drivers.

Qualitative findings were validated through expert workshops and cross-checked against operational indicators reported by transplant centers and specialty clinics. Where appropriate, sensitivity analyses and scenario planning were used to explore the effects of supply chain disruptions and policy changes on procurement and clinical continuity. Throughout, quality controls included source triangulation, transparency in assumptions, and iterative review by clinical subject-matter experts to ensure that conclusions reflect current practice and emerging trends in diagnostics, therapeutics, and care delivery.

Conclusion synthesizing clinical and strategic imperatives for improving graft longevity through diagnostics, therapeutics, collaboration, and resilient implementation strategies

Solid organ transplantation sits at a crossroads where scientific innovation, clinical practice, and system-level considerations converge to shape patient outcomes. Advances in diagnostics and therapeutics offer real potential to reduce the incidence and impact of acute, chronic, and hyperacute rejection, yet realizing that potential requires coordinated action across manufacturers, clinicians, health systems, and policymakers. Strategic investments in noninvasive monitoring, evidence generation, interoperable workflows, and resilient supply chains are central to translating scientific progress into routine clinical benefit.

In conclusion, stakeholders that align product development with clinical workflows, prioritize real-world validation, and invest in regional implementation strategies will be best positioned to improve graft survival and patient quality of life. Continued collaboration between hospitals and transplant centers, research institutes, and specialty clinics will drive the next wave of innovation and ensure that technological advances deliver measurable clinical value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Solid Organ Transplantation Rejection Market, by Rejection Type

  • 8.1. Acute Rejection
  • 8.2. Chronic Rejection
  • 8.3. Hyperacute Rejection

9. Solid Organ Transplantation Rejection Market, by Offering

  • 9.1. Diagnosis & Testing Solutions
    • 9.1.1. Blood Tests
    • 9.1.2. Imaging Tests
    • 9.1.3. Tissue Biopsy
  • 9.2. Medications
    • 9.2.1. Antibodies
    • 9.2.2. Antimetabolites
    • 9.2.3. Calcineurin Inhibitors
    • 9.2.4. Steroids

10. Solid Organ Transplantation Rejection Market, by Organ Type

  • 10.1. Heart
  • 10.2. Kidney
  • 10.3. Liver
  • 10.4. Lung
  • 10.5. Pancreas

11. Solid Organ Transplantation Rejection Market, by End User

  • 11.1. Hospitals & Transplant Centers
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Solid Organ Transplantation Rejection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Solid Organ Transplantation Rejection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Solid Organ Transplantation Rejection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Solid Organ Transplantation Rejection Market

16. China Solid Organ Transplantation Rejection Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Accord Healthcare Limited
  • 17.7. Asahi Kasei Corporation
  • 17.8. Astellas Pharma Inc.
  • 17.9. Biocon
  • 17.10. Cipla Ltd.
  • 17.11. Dr. Reddy's Laboratories Ltd.
  • 17.12. Eurofins Transplant Diagnostics
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. GlaxoSmithKline PLC
  • 17.15. Globela Pharma
  • 17.16. Lupin Limited
  • 17.17. Manus Aktteva Biopharma LLP
  • 17.18. Natco Pharma Ltd.
  • 17.19. Novartis AG
  • 17.20. Panacea Biotec Pharma Ltd.
  • 17.21. Pfizer Inc.
  • 17.22. Plexision
  • 17.23. Sanofi S.A.
  • 17.24. Strides Pharma Global Pte Ltd.
  • 17.25. Thermo Fisher Scientific Inc.
  • 17.26. Veloxis Pharmaceuticals A/S
  • 17.27. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ACUTE REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CHRONIC REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HYPERACUTE REJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY CALCINEURIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY PANCREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 136. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 157. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 164. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY REJECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY ORGAN TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA SOLID ORGAN TRANSPLANTATION REJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)